Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Hour chill reshape heart and brain function?

NCT ID NCT06076629

Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers at Fudan University are testing whether sitting in a 16°C room for two hours changes heart rate, blood pressure, lung function, or thinking speed in healthy young adults. Each participant will also spend time in a comfortable 22°C room for comparison. The study measures heart rhythm, breathing capacity, and cognitive tests to see how the body responds to cold. This could reveal how short cold spells affect basic body systems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low temperature exposure (16°C) compared with moderate temperature (22°C) in a chamber
What this could lead to
If cold exposure changes heart, lung, or brain function, this could inform how cold snaps affect health and guide advice for vulnerable people.
What could go wrong
This is a small, early study in healthy young adults, so results may not apply to older or sicker people. The effects measured are short-term and may not reflect real-world cold exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Oct 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Living in Shanghai during the study period; * Body mass index \> 18.5 and ≤ 28; * Right-handed; * Receiving or having received higher education; * With the ability to read and understand Chinese smoothly. Exclusion Criteria: * Smoking and alcohol abuse; * Current drug and dietary supplements intake; * Subjects with allergic diseases, such as allergic rhinitis, allergic asthma, and atopy; * Subjects with cardiovascular diseases, such as congenital heart disease, pulmonary heart disease, and hypertension; * Subjects with respiratory diseases, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease; * Subjects with chronic diseases, such as diabetes, chronic hepatitis, and kidney disease; * Subjects who have a history of major surgery due to cardiovascular, cerebrovascular, respiratory, or neurological diseases; * Subjects with neurologic disorders, such as stroke, traumatic brain injury, epilepsy, and schizophrenia; * Abnormal spirometry (FEV1 and FVC ≤ 75% of predicted and FEV1/FVC ≤ 0.65); * Subjects with color vision disabilities.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular system are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular system Cognitive function Respiratory system

Contacts and locations

Locations

  • Department of Environmental Health, School of Public Health, Fudan University

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.